 | Up a level |
Journal Article
Ahmadzadehfar, H., Albers, P., Bockisch, A., Boegemann, M., Boehme, C., Burchert, W., Dietlein, M., Drzezga, A., Fabry, U., Feldmann, G., Heidenreich, A., Heinzel, A., Herrmann, K., Heyll, A., Hoehling, C., Kreuzer, C., Laufer, D., Mengel, R., Mottaghy, F. M., Mueller, H-W., Mueller, S. C., Ost, E., Rahbar, K., Reifenhaeuser, W., Schaefers, M., Schlenkhoff, C., Schmidt, M., Schmidt-Wolf, I., Wildenhain, C., Zimmer, B. and Essler, M. (2018). Lutetium-177-PSMA radioligand therapy. Consensus within the framework of GKV-funded care between the university hospitals in Aachen, Bonn, Dusseldorf, Essen, and Cologne and the MDK Nordrhein. Urologe, 57 (6). S. 709 - 714. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1433-0563
Bacher, R., Dietlein, M., Kobe, C., Hohberg, M., Wild, M., Drzezga, A. and Schmidt, M. (2018). Retrospective comparison of thyroid and whole-body residence time of radioiodine in patients with differentiated thyroid carcinoma at initial ablative radioiodine therapy and follow-up whole-body scintigraphy after a short period of hypothyroidism or under rhTSH stimulation. Eur. J. Nucl. Med. Mol. Imaging, 45. S. S606 - 2. NEW YORK: SPRINGER. ISSN 1619-7089
Borchmann, P., Eichenauer, D., Pluetschow, A., Kreissl, S., Fuchs, M., Soekler, M., Engel, N., Mathas, S., Behringer, K., Kobe, C., Dietlein, M., Diehl, V. and Engert, A. (2014). TARGETED BEACOPP VARIANTS IN PATIENTS WITH NEWLY DIAGNOSED ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA: INTERIM RESULTS OF A RANDOMIZED PHASE II STUDY. Haematologica, 99. S. 497 - 499. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Borchmann, P., Goergen, H., Kobe, C., Fuchs, M., Greil, R., Zijlstra, J. M., Huettmann, A., Markova, J., Meissner, J., Feuring-Buske, M., Bentz, M., Dierlamm, J., Kuehnhardt, D., Lohri, A., Novak, U., Eichenauer, D., Eich, H., Baues, C., Stein, H., Diehl, V., Kuhnert, G., Dietlein, M. and Engert, A. (2017). TREATMENT REDUCTION IN PATIENTS WITH ADVANCED-STAGE HODGKIN LYMPHOMA AND NEGATIVE INTERIM PET: FINAL RESULTS OF THE INTERNATIONAL, RANDOMIZED PHASE 3 TRIAL HD18 BY THE GERMAN HODGKIN STUDY GROUP. Haematologica, 102. S. 24 - 26. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Borchmann, P., Kobe, C., Pluetschow, A., Greil, R., Meissner, J., Topp, M. S., Ostermann, H., Dierlamm, J., Mohm, J., Thiemer, J., Soekler, M., Kerkhoff, A., Ahlborn, M., Halbsguth, T., Martin, S., Keller, U., Balabanov, S., Pabst, T., Vogelhuber, M., Huettmann, A., Wilhem, M., Zijlstra, J. M., Moccia, A., Broeckelmann, P. J., von Tresckow, B., Fuchs, M., Eich, H., Baues, C., Hallek, M., Diehl, V, Dietlein, M. and Engert, A. (2020). Positron emission tomography guided omission of radiotherapy in early-stage unfavorable Hodgkin Lymphoma: Final results of the international, randomized Phase III HD17 trial by the German Hodgkin Study Group. Oncol. Res. Treat., 43 (SUPPL 4). S. 32 - 33. BASEL: KARGER. ISSN 2296-5262
Dietlein, M. and Drzezga, A. (2018). Ablative Radioiodine Therapy for treating Patients with Thyroid Cancer Standardized versus personalized De-escalation of I-131 Activity. Nuklearmedizin, 57 (4). S. 118 - 124. STUTTGART: GEORG THIEME VERLAG KG. ISSN 0029-5566
Dietlein, M., Kuhnert, G., Semrau, R., Nast-Kolb, B., Baues, C., Fuchs, M., Drzezga, A. and Kobe, C. (2014). Current importance of positron emission tomography in Hodgkin's lymphoma. Onkologe, 20 (5). S. 429 - 439. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1433-0415
Hammes, J., Hohberg, M., Taeger, P., Wild, M., Zlatopolskiy, B., Krapf, P., Neumaier, B., Schomaecker, K., Kobe, C., Schmidt, M., Dietlein, M. and Drzezga, A. (2018). Uptake In Non-affected Bone Tissue Does Not Differ Between [18f]-DCFPyL And [68Ga]-HBED-CC PSMA PET/CT. Eur. J. Nucl. Med. Mol. Imaging, 45. S. S535 - 1. NEW YORK: SPRINGER. ISSN 1619-7089
Hohberg, M., Dietlein, M., Kobe, C., Dietlein, F., Zlatopolskiy, B., Krapf, P., Wild, M., Taeger, P., Neumaier, B. and Drzezga, A. (2018). Biodistribution and radiation dosimetry of the novel F-18-labeled prostate-specific membrane antigen-ligand PSMA-7 for PET/CT in prostate cancer patients. Eur. J. Nucl. Med. Mol. Imaging, 45. S. S149 - 2. NEW YORK: SPRINGER. ISSN 1619-7089
Hohberg, M., Eschner, W., Schmidt, M., Dietlein, M., Kobe, C., Fischer, T., Drzezga, A. and Wild, M. (2016). Radiation dosimetry of organs and tissues at risk from Lu-177-DKFZ-PSMA-617 for prostate cancer therapy. Eur. J. Nucl. Med. Mol. Imaging, 43. S. S414 - 2. NEW YORK: SPRINGER. ISSN 1619-7089
Hohberg, M., Kobe, C., Taeger, P., Hammes, J., Schmidt, M., Dietlein, F., Wild, M., Heidenreich, A., Drzezga, A. and Dietlein, M. (2019). Combined Early and Late [Ga-68]PSMA-HBED-CC PET Scans Improve Lesion Detectability in Biochemical Recurrence of Prostate Cancer with Low PSA Levels. Mol. Imaging. Biol., 21 (3). S. 558 - 567. NEW YORK: SPRINGER. ISSN 1860-2002
Kobe, C., Dietlein, M., Borchmann, P., Engert, A., Kuhnert, G., Fuchs, M., Haverkamp, H., Eich, H. T., Kriz, J. and Diehl, V. (2011). PET-Response Adapted Therapy in Hodgkin Lymphoma. Eur. J. Cancer, 47. S. S16 - 1. OXFORD: ELSEVIER SCI LTD. ISSN 0959-8049
Kobe, C., Goergen, H., Fuchs, M., Eich, H. T., Baues, C., Diehl, V., Kuhnert, G., Drzezga, A., Dietlein, M., Engert, A. and Borchmann, P. (2017). Treatment Reduction in Patients with Advanced-Stage Hodgkin Lymphoma and Negative Interim FDG-PET: Final Results of the International, Randomized, Phase 3 HD18 Trial by the German Hodgkin Study Group. Eur. J. Nucl. Med. Mol. Imaging, 44. S. S312 - 1. NEW YORK: SPRINGER. ISSN 1619-7089
Kobe, C., Kuhnert, G., Haverkamp, H., Fuchs, M., Kahraman, D., Eich, H. -T., Kriz, J., Baues, C., Nast-Kolb, B., Broeckelmann, P. J., Borchmann, P., Drzezga, A., Engert, A. and Dietlein, M. (2015). Concordance in the interpretation of PET after chemotherapy in advanced stage Hodgkin lymphoma. Nuklearmedizin, 54 (6). S. 241 - 247. STUTTGART: GEORG THIEME VERLAG KG. ISSN 2567-6407
Kreissl, S., Goergen, H., Kobe, C., Fuchs, M., Greil, R., Huettmann, A., Meissner, J., Feuring-Buske, M., Bentz, M., Dierlamm, J., Kuehnhardt, D., Lohri, A., Novak, U., Eichenauer, D., Eich, H., Baues, C., Stein, H., Diehl, V., Kuhnert, G., Dietlein, M., Engert, A. and Borchmann, P. (2017). Treatment reduction in patients with advanced-stage-Hodgkin-lymphoma and negative interim PET: final results of the international randomized phase 3 trial HD18 by the German Hodgkin Study Goup. Oncol. Res. Treat., 40. S. 201 - 202. BASEL: KARGER. ISSN 2296-5262
Kuhnert, G., Boellaard, R., Kahramann, D., Scheffler, M., Wolf, J., Dietlein, M., Drzezga, A. and Kobe, C. (2015). PET/CT Reconstruction and Its Impact on Quantitative Image Analysis. Eur. J. Nucl. Med. Mol. Imaging, 42. S. S712 - 1. NEW YORK: SPRINGER. ISSN 1619-7089
Mettler, J., Chiapponi, C., Faust, M., Kunze, D. E., Kobe, C., Dietlein, M., Drzezga, A. E. and Schmidt, M. (2018). Influence on patient management after introduction of an interdisciplinary endocrine tumor board. Eur. J. Nucl. Med. Mol. Imaging, 45. S. S555 - 2. NEW YORK: SPRINGER. ISSN 1619-7089
Momotow, J., Sasse, S., Pluetschow, A., Huettmann, A., Basara, N., Koenecke, C., Martin, S., Bentz, M., Grosse-Thie, C., Thorspecken, S., de Wit, M., Kobe, C., Dietlein, M., von Tresckow, B., Fuchs, M., Borchmann, P. and Engert, A. (2020). AFM13 in patients with relapsed or refractory Hodgkin Lymphoma: Final results of an open-label, randomized, multicenter phase II trial. Oncol. Res. Treat., 43 (SUPPL 4). S. 89 - 90. BASEL: KARGER. ISSN 2296-5262
Pfestroff, A., Dietlein, M. and Luster, M. (2015). Nuclear medicine diagnostic procedures, treatment, and follow-up of thyroid carcinoma. Onkologe, 21 (7). S. 597 - 611. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1433-0415
Roesel, K., Schneider, C., Kobe, C., Dietlein, M., Drzezga, A. and Schmidt, M. C. (2015). Tc-99m MIBI-scintigraphy for malignancy risk assessment of hypofunctionning thyroid nodules. Eur. J. Nucl. Med. Mol. Imaging, 42. S. S66 - 2. NEW YORK: SPRINGER. ISSN 1619-7089
Scheffler, M., Bos, M., Sos, M., Nogova, L., Gardizi, M., Mattonet, C., Papachristou, I., Kahraman, D., Kobe, C., Lammertsma, A., Boellaard, R., Persigehl, T., Heukamp, L., Buettner, R., Elter, T., Toepelt, K., Engel-Riedel, W., Stoelben, E., Neumaier, B., Dietlein, M., Zander, T. and Wolf, J. (2014). MIMEB: A phase II trial to evaluate FDG-PET/FLT-PET and DCE-MRI for early prediction of efficacy in patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab. Oncol. Res. Treat., 37. S. 92 - 93. BASEL: KARGER. ISSN 2296-5262
Schmidt, M. C., Pfister, O., Kobe, C., Dietlein, M., Dietlein, M., Heidenreich, A. and Drzezga, A. (2017). Tc-99m-PSMA-guided intraoperative lymph node localization in recurrent prostate cancer. Eur. J. Nucl. Med. Mol. Imaging, 44. S. S750 - 2. NEW YORK: SPRINGER. ISSN 1619-7089
Taeger, P. A., Hammes, J., Hohberg, M., Wild, M., Schomaecker, K., Kobe, C., Pfister, D., Heidenreich, A., Dietlein, M., Schmidt, M. and Drzezga, A. (2018). Discrete evaluation of multi-cycle Lu-177-PSMA-617-therapy effects on bone versus lymph node metastases in patients with metastasized castrationresistant prostate cancer (mCRPC). Eur. J. Nucl. Med. Mol. Imaging, 45. S. S126 - 1. NEW YORK: SPRINGER. ISSN 1619-7089
Voltin, C., Stockter, S., Baues, C., Fuchs, M., Dietlein, M., Mettler, J., Engert, A., Borchmann, P., Drzezga, A. and Kobe, C. (2017). Staging Patients with Hodgkin Lymphoma - Is Bone Marrow Biopsy Still Necessary in the Era of F-18-FDG PET? Eur. J. Nucl. Med. Mol. Imaging, 44. S. S244 - 2. NEW YORK: SPRINGER. ISSN 1619-7089
Voltin, C. -A., Goergen, H., Baues, C., Fuchs, M., Mettler, J., Kreissl, S., Oertl, J., Klaeser, B., Moccia, A., Drzezga, A., Engert, A., Borchmann, P., Dietlein, M. and Kobe, C. (2018). Value of bone marrow biopsy in Hodgkin lymphoma patients staged by FDG PET: results from the German Hodgkin Study Group trials HD16, HD17, and HD18. Ann. Oncol., 29 (9). S. 1926 - 1932. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041